LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Haemonetics Corp

Gesloten

SectorGezondheidszorg

57.45 -3.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

57.02

Max

59.12

Belangrijke statistieken

By Trading Economics

Inkomsten

6.1M

45M

Verkoop

12M

339M

K/W

Sectorgemiddelde

15.893

121.746

EPS

1.31

Winstmarge

13.199

Werknemers

3,023

EBITDA

8.7M

95M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+44.12% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-469M

2.7B

Vorige openingsprijs

60.83

Vorige sluitingsprijs

57.45

Nieuwssentiment

By Acuity

50%

50%

149 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Haemonetics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2026, 23:47 UTC

Populaire aandelen

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Winsten
Acquisities, Fusies, Overnames

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Winsten

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Winsten

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Winsten

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Winsten

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Winsten

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Winsten

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Marktinformatie

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Marktinformatie

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Marktinformatie

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Winsten

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Winsten

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Winsten

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Winsten

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Winsten

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Winsten

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Winsten

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Vergelijking

Prijswijziging

Haemonetics Corp Prognose

Koersdoel

By TipRanks

44.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 83.14 USD  44.12%

Hoogste 94 USD

Laagste 74 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Haemonetics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

4

Buy

4

Hold

0

Sell

Technische score

By Trading Central

62.51 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

149 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
help-icon Live chat